<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085760</url>
  </required_header>
  <id_info>
    <org_study_id>08-008247</org_study_id>
    <nct_id>NCT01085760</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis</brief_title>
  <acronym>PSC</acronym>
  <official_title>A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PSC Partners Seeking a Cure Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Vancomycin or Metronidazole is safe and
      beneficial in the treatment of Primary Sclerosing Cholangitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this protocol, we propose the assessment of potential beneficial effects of the
      antibiotics vancomycin and metronidazole on liver biochemistries, liver related symptoms and
      Mayo risk score in patients with PSC. The patients will be randomized into four groups of ten
      patients: one group will receive low dose vancomycin, one group will receive high dose
      vancomycin, one group will receive low dose metronidazole and one group will receive high
      dose metronidazole. Each group will be treated for three months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alkaline Phosphatase Following 12 Weeks of Treatment</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Bilirubin Following 12 Weeks Treatment</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mayo PSC Risk Score Following 12 Weeks of Treatment</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The Mayo PSC risk score was calculated for each patient at baseline and at 12 weeks, where Risk = 0.03 (age [years]) + 0.54 Ln (total bilirubin [mg/dL]) + 0.54 Ln (AST [IU/L]) + 1.24 (variceal bleeding) - 0.84 (albumin [g/dL]). There is no range, minimum, or maximum value but greater values indicate worse disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein Following 12 Weeks of Treatment</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Vancomycin 125 mg orally 4 times a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin 250 mg orally 4 times a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole 250 mg orally 3 times a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole 500 mg orally 3 times a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>Vancomycin 125 mg orally 4 times a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>Vancomycin 250 mg orally 4 times a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>Metronidazole 250 mg orally 3 times a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Comparison of different doses of drug</description>
    <arm_group_label>Metronidazole 500 mg orally 3 times a day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Comparison of different drug doses</description>
    <arm_group_label>Vancomycin 125 mg orally 4 times a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PSC established by alkaline phosphatase &gt;1.5 times and/or two fold
             elevation of liver transaminases (AST and/or ALT) for at least 6 months duration.

          -  Cholangiography demonstrating intrahepatic and/or extrahepatic biliary obstruction,
             beading, or narrowing consistent with PSC.

          -  Both genders.

          -  Age â‰¥ 18 years old and &lt; than 75 years old.

          -  Patient's informed consent for study participation.

        Exclusion Criteria:

          -  Treatment with systematic antibiotics, azulfidine, ursodeoxycholic acid,
             corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil,
             budesonide, pentoxifylline, tacrolimus, silymarin or prednisone in the preceding three
             months.

          -  Active drug or alcohol use.

          -  Prior history of allergic reactions to the antibiotics which will be used in the
             study.

          -  Any condition that, in the opinion of the investigator, would interfere with the
             patients' ability to complete the study safely or successfully.

          -  Evidence of decompensated liver disease such as recurrent variceal bleeding,
             refractory ascites or spontaneous hepatic encephalopathy.

          -  Anticipated need for transplantation in one year (Mayo survival model &lt;80% one-year
             survival without transplant).

          -  Findings highly suggestive of liver disease of other etiology such as chronic
             alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's
             disease, 1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary
             cirrhosis or secondary sclerosing cholangitis.

          -  Pregnancy or current lactation. Subjects becoming pregnant during the study will be
             withdrawn.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayant A Talwalkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <results_first_submitted>November 2, 2012</results_first_submitted>
  <results_first_submitted_qc>July 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2013</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jayant A. Talwalkar</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 35 adult patients with primary sclerosing cholangitis (PSC) were enrolled between February 2010 and November 2011 at Mayo Clinic, Rochester MN.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Vancomycin</title>
          <description>Vancomycin 125 mg 4 times a day</description>
        </group>
        <group group_id="P2">
          <title>High Dose Vancomycin</title>
          <description>Vancomycin 250 mg 4 times a day</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Metronidazole</title>
          <description>Metronidazole 250 mg 3 times a day</description>
        </group>
        <group group_id="P4">
          <title>High Dose Metronidazole</title>
          <description>metronidazole 500 mg 3 times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Vancomycin</title>
          <description>Vancomycin 125 mg 4 times a day</description>
        </group>
        <group group_id="B2">
          <title>High Dose Vancomycin</title>
          <description>Vancomycin 250 mg 4 times a day</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Metronidazole</title>
          <description>Metronidazole 250 mg 3 times a day</description>
        </group>
        <group group_id="B4">
          <title>High Dose Metronidazole</title>
          <description>metronidazole 500 mg 3 times a day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="20" upper_limit="60"/>
                    <measurement group_id="B2" value="42" lower_limit="27" upper_limit="70"/>
                    <measurement group_id="B3" value="35" lower_limit="21" upper_limit="64"/>
                    <measurement group_id="B4" value="40" lower_limit="20" upper_limit="60"/>
                    <measurement group_id="B5" value="40" lower_limit="20" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alkaline Phosphatase Following 12 Weeks of Treatment</title>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The number of participants was based on a per protocol analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vancomycin</title>
            <description>Vancomycin 125 mg 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vancomycin</title>
            <description>Vancomycin 250 mg 4 times a day</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Metronidazole</title>
            <description>Metronidazole 250 mg 3 times a day</description>
          </group>
          <group group_id="O4">
            <title>High Dose Metronidazole</title>
            <description>Metronidazole 500 mg 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alkaline Phosphatase Following 12 Weeks of Treatment</title>
          <population>The number of participants was based on a per protocol analysis.</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-117" lower_limit="-304" upper_limit="165"/>
                    <measurement group_id="O2" value="-49" lower_limit="-315" upper_limit="18"/>
                    <measurement group_id="O3" value="-62" lower_limit="-502" upper_limit="212"/>
                    <measurement group_id="O4" value="-36" lower_limit="-450" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Bilirubin Following 12 Weeks Treatment</title>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>Per protocol analysis done</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vancomycin</title>
            <description>Vancomycin 125 mg 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vancomycin</title>
            <description>Vancomycin 250 mg 4 times a day</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Metronidazole</title>
            <description>Metronidazole 250 mg 3 times a day</description>
          </group>
          <group group_id="O4">
            <title>High Dose Metronidazole</title>
            <description>Metronidazole 500 mg 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin Following 12 Weeks Treatment</title>
          <population>Per protocol analysis done</population>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-0.9" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.05" lower_limit="-0.8" upper_limit="9.7"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.5" upper_limit="0"/>
                    <measurement group_id="O4" value="0.05" lower_limit="-0.5" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mayo PSC Risk Score Following 12 Weeks of Treatment</title>
        <description>The Mayo PSC risk score was calculated for each patient at baseline and at 12 weeks, where Risk = 0.03 (age [years]) + 0.54 Ln (total bilirubin [mg/dL]) + 0.54 Ln (AST [IU/L]) + 1.24 (variceal bleeding) â€“ 0.84 (albumin [g/dL]). There is no range, minimum, or maximum value but greater values indicate worse disease.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vancomycin</title>
            <description>Vancomycin 125 mg 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vancomycin</title>
            <description>Vancomycin 250 mg 4 times a day</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Metronidazole</title>
            <description>Metronidazole 250 mg 3 times a day</description>
          </group>
          <group group_id="O4">
            <title>High Dose Metronidazole</title>
            <description>Metronidazole 500 mg 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mayo PSC Risk Score Following 12 Weeks of Treatment</title>
          <description>The Mayo PSC risk score was calculated for each patient at baseline and at 12 weeks, where Risk = 0.03 (age [years]) + 0.54 Ln (total bilirubin [mg/dL]) + 0.54 Ln (AST [IU/L]) + 1.24 (variceal bleeding) â€“ 0.84 (albumin [g/dL]). There is no range, minimum, or maximum value but greater values indicate worse disease.</description>
          <population>Per protocol analysis</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-1.13" upper_limit="0.21"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.71" upper_limit="1.15"/>
                    <measurement group_id="O3" value="-0.26" lower_limit="-0.75" upper_limit="0.09"/>
                    <measurement group_id="O4" value="-0.20" lower_limit="-0.64" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein Following 12 Weeks of Treatment</title>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>Per protocol analysis done</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Vancomycin</title>
            <description>Vancomycin 125 mg 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>High Dose Vancomycin</title>
            <description>Vancomycin 250 mg 4 times a day</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Metronidazole</title>
            <description>Metronidazole 250 mg 3 times a day</description>
          </group>
          <group group_id="O4">
            <title>High Dose Metronidazole</title>
            <description>Metronidazole 500 mg 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein Following 12 Weeks of Treatment</title>
          <population>Per protocol analysis done</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-47.3" upper_limit="0"/>
                    <measurement group_id="O2" value="1" lower_limit="-5.6" upper_limit="28.6"/>
                    <measurement group_id="O3" value="-3.6" lower_limit="-17.4" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="-1.9" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Vancomycin</title>
          <description>Vancomycin 125 mg 4 times a day</description>
        </group>
        <group group_id="E2">
          <title>High Dose Vancomycin</title>
          <description>Vancomycin 250 mg 4 times a day</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Metronidazole</title>
          <description>Metronidazole 250 mg 3 times a day</description>
        </group>
        <group group_id="E4">
          <title>High Dose Metronidazole</title>
          <description>metronidazole 500 mg 3 times a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>burning in eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>metallic taste</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>increased fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>numbness and tingling of extremities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>increased itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jayant A. Talwalkar</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-538--4877</phone>
      <email>talwalkar.jayant@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

